Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2390 in Adult Subjects Allergic to House Dust Mites
NCT04184895Phase 1Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of ASP2390 in allergic rhinitis (AR) (4 cohorts), sponsored by Astellas Pharma. Primary endpoints: Number of participants with Adverse Events, Number of participants with laboratory value abnormalities and/or AEs and 5 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
ASP2390
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04184895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184895.